Sotoxen contains Sotorasib, a selective KRAS G12C inhibitor indicated for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation, who have received at least one prior systemic therapy. Sotorasib selectively targets KRASG12C, an oncogenic driver in many cancers, inhibiting tumor cell signaling, growth, and promoting apoptosis.

By covalently binding the unique cysteine in KRASG12C, Sotorasib locks the protein in an inactive state, blocking downstream oncogenic pathways without affecting wild-type KRAS, ensuring selective anti-tumor activity. Preclinical studies have shown Sotorasib also promotes anti-tumor immune responses in KRASG12C-expressing tumors.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

• KRAS G12C-mutated NSCLC (locally advanced or metastatic)

• Patients who have received at least one prior systemic therapy

• Therapy guided by an FDA-approved KRAS G12C test

Pharmacology

• Mechanism of Action: Covalent, irreversible inhibition of KRAS G12C

• Effect: Blocks tumor cell signaling, inhibits growth, induces apoptosis

• Selectivity: Minimal off-target activity; locks KRASG12C in inactive state

• Additional Effects: Enhances antigen presentation and inflammatory cytokine production selectively in KRASG12C tumor cells

Dosage & Administration

• Recommended Dose: 960 mg orally once daily (eight 120 mg tablets)

• Administration: With or without food; swallow tablets whole

• Missed Dose: If >6 hours late, take next dose at usual time; do not double dose

• Vomiting: Do not take an additional dose; continue next day as scheduled

• Treatment Duration: Continue until disease progression or unacceptable toxicity

Drug Interactions

• Acid-reducing agents: Avoid PPIs, H2 blockers, and antacids if possible; if necessary, adjust timing

• CYP3A4 inducers: Avoid strong inducers (e.g., rifampicin, carbamazepine)

• CYP3A4 substrates: Avoid co-administration with sensitive substrates; may require dose adjustment

• P-gp substrates: Caution with digoxin and other P-gp substrates; monitor for toxicity

Side Effects

• Hepatotoxicity: Liver dysfunction including elevated AST, ALT, bilirubin, or drug-induced hepatitis

• Interstitial Lung Disease (ILD)/Pneumonitis: Rare but potentially fatal; monitor for respiratory symptoms

• Monitoring: Regular liver function tests every 3 weeks for first 3 months, then monthly

Precautions & Warnings

• Hepatotoxicity: May require dose interruption, reduction, or permanent discontinuation

• ILD/Pneumonitis: Immediately withhold if suspected; permanently discontinue if no alternative cause found

• Patient Monitoring: Liver function, respiratory symptoms, and overall tolerance

• Other Risks: Reproductive toxicity in animal studies; unknown effects in pregnancy and lactation

Pregnancy & Lactation

• Pregnancy: No human data; animal studies show reproductive toxicity

• Breastfeeding: Unknown if excreted in human milk; weigh benefits of therapy vs. breastfeeding

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Overdose

• No clinical experience with overdose

• Management: Symptomatic and supportive care as needed

Therapeutic Class

• Cytotoxic Chemotherapy / KRAS G12C Inhibitor

Storage Conditions

• Store below 25°C in a cool, dry place, protected from light

• Keep out of reach of children